The International Liver Congress™ 2011 by EASL (46th annual meeting)
Will Take Place On March 30-April 3, 2011
Internationales Congress Centrum (ICC) Berlin, Germany
The International Liver Congress™ 2011 by EASL provides an opportunity for around 7,500 clinicians & scientists from around the world to receive the latest research developments & treatment options.
A summary will be provided after the meeting
Watch for EASL News Updates; Posted In The Order They Are Received
The International Liver Congress™ 2011 by EASL (46th annual meeting)
EASL Website
Upcoming Oral Presentations
Abstracts/Poster Sessions
Thursday, 31, March – Saturday 2 April
• LBP01: Category 15: Late-Breakers
31 MAR, 2011
• P1.02B: Category 02b: Cirrhosis and its complications: Clinical aspects
• P1.05: Category 05: Liver Immunology including Viral Hepatitis
• P1.06: Category 06: Non-invasive markers of liver fibrosis
• P1.07B: Category 07b: Viral Hepatitis B & D: Clinical (except therapy)
• P1.08C: Category 08c: Viral Hepatitis C: Clinical (therapy)
• P1.11: Category 11: Alcoholic liver disease and drug induced liver disease
• P1.3A: Category 03a: Liver tumors: Experimental
01 APR, 2011
• P2.01A: Category 01a: Liver transplantation / surgery: Experimental
• P2.01B: Category 01b: Liver transplantation / surgery: Clinical
• P2.02A: Category 02a: Cirrhosis and its complications: Pathophysiology
• P2.03C: Category 03c: Liver tumors: Management
• P2.04A: Category 04a: Molecular and cellular biology: Cell cycle control / apoptosis
• P2.04B: Category 04b: Molecular and cellular biology: Biliary tract pathophysiology
• P2.07C: Category 07c: Viral Hepatitis B & D: Clinical (therapy, new compounds, resistance)
• P2.08A: Category 08a: Viral Hepatitis C: Experimental (virology)
• P2.10B: Category 10b: Fatty Liver Disease: Clinical
• P2.13: Category 13: Genetic and pediatric liver diseases
02 APR, 2011
• P3.01C: Category 01c: Liver transplantation / surgery: Acute liver failure – clinical & experimental
• P3.02C: Category 02c: Cirrhosis and its complications: Bleeding
• P3.02D: Category 02d: Cirrhosis and its complications: Hepatorinal syndrome and ascitis
• P3.03B: Category 03b: Liver tumors: Clinical (epidemiology, diagnosis)
• P3.04C: Category 04c: Molecular and cellular biology: HSCs and fibrosis
• P3.04D: Category 04d: Molecular and cellular biology: Liver regeneration
• P3.07A: Category 07a: Viral Hepatitis B & D: Experimental
• P3.08B: Category 08b: Viral Hepatitis C: Clinical (except therapy)
• P3.08D: Category 08d: Viral Hepatitis C: Clinical (new compounds, resistance)
• P3.09: Category 09: Viral Hepatitis A and E
• P3.10A: Category 10a: Fatty Liver Disease: Experimental
• P3.12: Category 12: Autoimmune and chronic cholestatic liver diseases
• P3.14: Category 14: IL28b Polymorphism
Presentation at EASL Annual Meeting ;Updates
Telaprevir and VX-222
Vertex announced 15 abstracts for hepatitis C, including its protease inhibitor, telaprevir, and polymerase inhibitor, VX-222, were accepted for presentation at EASL in Berlin, Germany. March 30 to April 3, 2011.
Hepatitis C Drug Telaprevir and VX-222 Accepted For Presentation at EASL
New Data on Telaprevir and VX-222 for the Treatment of Hepatitis C Accepted For Presentation at EASL Annual Meeting - Complete results from pivotal Phase 3 REALIZE study of telaprevir in people who had not achieved a viral cure (SVR) with currently available medicines -- First presentation of data from ongoing Phase 2 study evaluating response-guided, 12- and 24-week regimens of telaprevir and VX-222 combined with pegylated-interferon and ribavirin -- Analyses of the relationship between IL28B genotype status on viral cure rates from twoPhase 3 studies -CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that 15 abstracts on the company’s medicines in development for hepatitis C, including its protease inhibitor, telaprevir, and polymerase inhibitor, VX-222, were accepted for presentation at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) in Berlin, Germany, March 30 to April 3, 2011.“Telaprevir in Combination with Peginterferon Alfa-2a and Ribavirin Increased Sustained...See Press Release
.
Boceprevir
March 07, 2011 10:44 AM Eastern Time
.Merck Announces New Data Analyses for VICTRELIS™ (Boceprevir) will be Presented at The International Liver CongressTM / 2011 EASL Annual Meeting
. .WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that several new data analyses from Phase III studies of VICTRELIS™ (boceprevir), its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver (EASL) annual meeting. The meeting will be held from March 30 – April 3 in Berlin. In total, more than 20 abstracts highlighting Merck medicines and investigational therapies for chronic hepatitis C virus (HCV) infection will be presented, including 3 oral presentations and 17 posters for VICTRELIS.
“How should I dispose of the used syringes, needles, and vials?”
Presented for the first time will be final results from a Phase III study of VICTRELIS administered in combination with Pegasys® (peginterferon alfa-2a) and ribavirin in adult patients with chronic HCV genotype 1 infection who were non-responders or relapsers to previous pegylated interferon and ribavirin therapy.
The EASL presentations will also include new analyses of the pivotal Phase III data for VICTRELIS administered in combination with PEGINTRON® (peginterferon alfa-2b) and ribavirin from the HCV SPRINT-2 and HCV RESPOND-2 studies:
Response-guided therapy with VICTRELIS in combination with current standard therapy among patients with chronic HCV genotype 1, including special populations such as those with advanced fibrosis / cirrhosis;
Overall safety profile of VICTRELIS administered in combination with current standard therapy for chronic HCV; and
Potential predictive factors for chronic HCV treatment success, including response following 4 weeks of lead-in therapy and IL28B polymorphism.
The abstracts were published today and can be accessed on the EASL website. For program information, please visit http://www2.kenes.com/liver-congress/Pages/Home.aspx.
See Full Press Release.............
.Peregrine's Bavituximab HCV Abstract Accepted for Presentation at the 46th Annual Meeting of EASLTUSTIN, CA--(Marketwire - March 7, 2011) - Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that data from the company's Phase Ib dose escalation safety study of bavituximab in patients coinfected with chronic hepatitis C virus (HCV) and HIV has been accepted for presentation at the 46th annual meeting of the European Association for the Study of the Liver (EASL) taking place in Berlin, Germany from March 30 to April 3, 2011.
The abstract can be accessed through the EASL website http://www2.kenes.com/liver-congress/Pages/Home.aspx. In accordance with the EASL embargo policy, the accepted abstract titled "Escalating Repeat Dose Study of Bavituximab in Patients Co-infected with Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus" (poster 1239) will be presented in a poster session on Saturday, April 2, 2011.
About Peregrine PharmaceuticalsPeregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®.
Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (http://ctt.marketwire.com/?release=729095&id=142513&type=1&url=http%3a%2f%2fwww.avidbio.com%2f), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com/.
.
NS5A inhibitor BMS-790052 in combination with PEG-Interferon alpha-2a and ribavirin (IFN?/RBV) in treatment-naïve HCV patients. Additionally, SVR 12-week data on quadruple therapy with BMS-790052, the NS3 inhibitor BMS-650032 and IFN?/RBV in null responders
.
BRISTOL-MYERS SQUIBBDL-10 : New Data on Multiple Bristol-Myers Squibb Investigational Hepatitis C Compounds to be Presented at The International Liver Congress
2011 03/07/2011 01:55 pm
.
New Phase II data on multiple Bristol-Myers Squibb Company (NYSE: BMY) investigational hepatitis C compounds will be presented at The International Liver Congress (ILC), the 46th annual meeting of the European Association for the Study of the Liver (EASL) in Berlin, Germany, from March 30 to April 2. The data presentations, including three late-breaker presentations, demonstrate the rigorous execution of the company's strategy to develop potential improvements in the care of patients living with Hepatitis C infection by using multiple approaches to target the virus. Bristol-Myers Squibb will present three late-breaker presentations, including a poster presentation of the first public disclosure of 12-week data on sustained virologic response (SVR) with the NS5A inhibitor BMS-790052 in combination with PEG-Interferon alpha-2a and ribavirin (IFN?/RBV) in treatment-naïve HCV patients. Additionally, SVR 12-week data on quadruple therapy with BMS-790052, the NS3 inhibitor BMS-650032 and IFN/RBV in null responders will be presented in the late-breaker oral presentation session on Saturday, April 2. Complete early virology response (cEVR) data from the Phase IIb EMERGE study of PEG-Interferon lambda and ribavirin versus IFN?/RBV in treatment-naïve patients will also be presented in a late-breaker oral presentation.
Full Press Release.........
.
IDX184 in Genotype 1-Infected HCV Subjects
.
Idenix Announces Data Presentations at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL)
.
CAMBRIDGE, Mass., March 7, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that two abstracts have been accepted for presentation at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL, March 30- April 3, 2011 in Berlin, Germany). Full abstracts can now be viewed at the EASL website at http://www.easl.eu/ .
The accepted abstracts are as follows:
Standring, et al, "Idenix NS5A HCV Replication Inhibitors with Low Picomolar, Pan-Genotypic in vitro Antiviral Activity" will be presented in a poster session beginning on Friday, April 1.
Standring, et al, "No Resistance to IDX184 Was Detected in 3-day and 14-day Clinical Studies of IDX184 in Genotype 1-Infected HCV Subjects" will be presented in a poster session on Saturday, April 2.
About Idenix
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus. For further information about Idenix, please refer full press release http://www.idenix.com/.
.
Hepatitis C: IMO-2125 Data will be presented at EASL
.
Idera Pharmaceuticals Announces IMO-2125 Data Presentation at the 46th Annual Meeting of the European Association for the Study of the LiverIdera Pharmaceuticals Inc. Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that data from its Phase 1 clinical trial of IMO-2125, its novel immune modulator for the treatment of chronic hepatitis C virus (HCV) infection, in treatment-naïve genotype 1 HCV patients will be presented at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) being held March 30 – April 3, 2011 in Berlin, Germany.The presentation entitled "IMO-2125 plus ribavirin gives substantial first-dose viral load reductions, cumulative antiviral effect, is well tolerated in naïve genotype 1 HCV patients: a Phase 1 trial,” D. Guyader, et al., will be made in a poster session entitled Viral Hepatitis C: Clinical (new compounds, resistance) on Saturday, April 2, 2011. The full abstract (#1209) can now be accessed through the EASL website http://www.easl.eu/.
About IMO-2125IMO-2125, a Toll-like Receptor (TLR) 9 agonist, is a novel immune modulator being developed as a component of treatment for chronic hepatitis C virus (HCV) infection. IMO-2125 is designed to stimulate the immune system, causing the body to generate natural interferons and other antiviral cytokines. IMO-2125 has been evaluated in a Phase 1 clinical trial in null-responder HCV patients, defined as those who did not achieve a 2 log10 reduction with prior standard of care treatment, as monotherapy for 4 weeks and in a Phase 1 clinical trial in treatment-naïve HCV patients in combination with ribavirin for 4 weeks.
http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=37280
.
No comments:
Post a Comment